Gold prices slid below $4,000/oz amid profit-taking on Gaza ceasefire
A ten percent owner, Reprogrammed Interchange LLC, of Vor Biopharma Inc (NASDAQ:VOR) and Reid Hoffman, deemed beneficial owner, reported selling a combined total of 984,805 shares of common stock in multiple transactions. According to InvestingPro data, the company, currently valued at approximately $199 million, appears undervalued based on its Fair Value analysis. The sales occurred between September 11 and September 15, 2025, with prices ranging from $1.6408 to $1.8308, totaling approximately $1.7 million. These transactions came during a volatile period for VOR’s stock, which has shown significant price swings with a beta of 2.05 and has delivered a remarkable 94% return over the past six months.
On September 11, 284,805 shares were sold at a weighted average price of $1.8308. The price for these shares ranged from $1.81 to $1.855. Following this transaction, the reporting owners still held 33,928,487 shares.
The sales continued on September 12, with 300,000 shares sold at a weighted average price of $1.7541, in a range of $1.73 to $1.85. After this transaction, the reporting owners held 33,628,487 shares.
The final reported transaction occurred on September 15, with 400,000 shares sold at a weighted average price of $1.6408. The prices for these shares ranged from $1.57 to $1.765. Following this transaction, the reporting owners held 33,228,487 shares.
Reid Hoffman disclaims beneficial ownership of the securities held by Reprogrammed Interchange LLC, except to the extent of his pecuniary interest therein. For deeper insights into insider trading patterns and comprehensive analysis of VOR’s financial health, including 14 additional ProTips and detailed valuation metrics, visit InvestingPro.
In other recent news, Vor Biopharma Inc. announced significant developments concerning its board of directors. The company revealed the resignations of Joshua Resnick, M.D., Matthew Patterson, and David Lubner from the board, with none of these resignations stemming from disagreements with the company. In a related move, Vor Biopharma appointed Alexander (Bo) Cumbo and Michel Detheux, Ph.D., to its board, effective July 2025. Additionally, Vor Biopharma shared positive results from its collaboration with RemeGen Co., Ltd, as their joint Phase 3 clinical study for telitacicept in adults with IgA nephropathy (IgAN) met its primary endpoint. The study showed a significant 55% reduction in the 24-hour urine protein-to-creatinine ratio at 39 weeks. Furthermore, Vor Biopharma’s shareholders approved changes to the company’s 2021 Equity Incentive Plan, increasing the number of shares reserved for issuance by 25 million. The amendment also adjusted the annual automatic increase in the share reserve from 5% to 4% of outstanding shares through 2035. These developments provide a snapshot of the company’s recent strategic and operational activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.